Dexmedetomidine Protects Cardiomyocytes against Hypoxia/Reoxygenation Injury by Suppressing TLR4-MyD88-NF-κB Signaling

Figure 1

DEX pretreatment attenuates cell damage and inflammation in cardiomyocytes exposed to H/R. Viability of H9C2 cells and rat neonatal cardiomyocytes was measured by MTT (a, b) and LDH activity (c, d). Data are expressed as means ± SEM ( = 5 per group). IL-1β, TNF-α, and IL-6 expression was evaluated by quantitative RT-PCR (e–j). Data are expressed as means ± SEM ( = 3 per group). < 0.01 versus control group; < 0.05, < 0.01 versus H/R group. D: DEX.

(a) H9C2 cells

(b) Neonatal cardiomyocytes

(c) H9C2 cells

(d) Neonatal cardiomyocytes

(e) H9C2 cells

(f) Neonatal cardiomyocytes

(g) H9C2 cells

(h) Neonatal cardiomyocytes

(i) H9C2 cells

(j) Neonatal cardiomyocytes